Oncology Research and Treatment最新文献

{"title":"Epidemiology, Real-World Treatment Patterns, and Patient Outcomes of Primary Advanced or Recurrent Endometrial Cancer in Germany between 2015 and 2021.","authors":"Antje Mevius, Johanna Lutter, Florian M Karl, Liam Tuffy, Fabienne Schochter, Andreas Fuchs, Thomas Wilke","doi":"10.1159/000542773","DOIUrl":"10.1159/000542773","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to describe the epidemiology of primary advanced or recurrent endometrial cancer and the outcomes from real-world treatment patterns of patients affected in Germany between 2015 and 2021.</p><p><strong>Methods: </strong>In this retrospective cohort study covering the period from 1 January 2015 to 31 December 2021, data from patients with primary advanced or recurrent endometrial cancer who initiated systemic treatment for their disease were extracted from an anonymized claims dataset from a regional health insurance fund in the German states of Saxony and Thuringia. Epidemiologic outcomes were cumulative incidence of endometrial cancer and point prevalence. Overall survival after the index date was assessed, with all-cause death used as an event. Endometrial cancer-related real-world treatment patterns were described for the post-index period.</p><p><strong>Results: </strong>The incidence of primary advanced or recurrent endometrial cancer in 2021 was 4.77 cases/100,000 persons, with no substantial change over time (4.63 in 2018; 4.93 in 2019; 4.45 in 2020). The point prevalence on 1 January 2022 was 0.023%, with a slight increase in prevalence observed from 1 January 2019 onwards. Among 466 patients with confirmed endometrial cancer, the mean (standard deviation) age was 68.0 (11.6) years; the tumor material from 86 patients (18.5%) underwent immunohistochemistry or polymerase chain reaction testing. Median overall survival was estimated to be 47.5 months (95% CI: 35.1-70.4) and the 5-year survival probability was 46.2%. The most frequent first-line systemic therapies were carboplatin (45.7%) and paclitaxel (43.1%). Second-line therapy was received by 153 patients (32.8%).</p><p><strong>Conclusion: </strong>The analysis of the German claims data produced contemporary epidemiologic estimates for advanced or recurrent endometrial cancer. Treatments were aligned with guideline recommendations during the study period, with tumor testing yet to enter mainstream practice.</p><p><strong>Introduction: </strong>The aim of this study was to describe the epidemiology of primary advanced or recurrent endometrial cancer and the outcomes from real-world treatment patterns of patients affected in Germany between 2015 and 2021.</p><p><strong>Methods: </strong>In this retrospective cohort study covering the period from 1 January 2015 to 31 December 2021, data from patients with primary advanced or recurrent endometrial cancer who initiated systemic treatment for their disease were extracted from an anonymized claims dataset from a regional health insurance fund in the German states of Saxony and Thuringia. Epidemiologic outcomes were cumulative incidence of endometrial cancer and point prevalence. Overall survival after the index date was assessed, with all-cause death used as an event. Endometrial cancer-related real-world treatment patterns were described for the post-index period.</p><p><strong>Resul","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"92-101"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11878414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort.","authors":"Stefanie Hegenberg, Tobias Germing, Elena Schlageter, Ira Ekmekciu, Jens Christmann, Andrea Tannapfel, Anke Reinacher-Schick","doi":"10.1159/000543997","DOIUrl":"10.1159/000543997","url":null,"abstract":"<p><strong>Introduction: </strong>Pancreatic ductal adenocarcinoma (PDAC) is a challenging malignancy and precision oncology treatment options may improve patient outcomes. Next-generation sequencing (NGS) is an established tool that enables multigene panel analysis.</p><p><strong>Methods: </strong>This NGS tissue-based analysis, conducted at a German pancreatic cancer center, included 128 patients between January 2016 and January 2021.</p><p><strong>Results: </strong>A targetable lesion was detected in 15.6% of patients. BRCA1/2 mutations were identified in 16 patients, of whom 13 had germline mutations; 8 of these patients received olaparib. In 41.4% of patients, homologous recombination repair genes were affected. Two cases of ATP1B1-NRG1 fusions and seven cases of dMMR tumors were found, leading to individualized treatment. KRAS mutations were present in 70.3%, and TP53 mutations were present in 63.3%. A total of 80.5% of patients received platinum-based chemotherapy, predominantly FOLFIRINOX.</p><p><strong>Conclusion: </strong>The high frequency of targetable alterations in our cohort underscores upfront NGS testing in PDAC. Younger patients, those with a positive family history, and KRAS WT patients should be of particular interest.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"256-264"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2(-Low) Expression on Circulating Tumor Cells and Corresponding Metastatic Tissue in Metastatic Breast Cancer.","authors":"Lara M Tretschock, Hannah Clemente, Katharina Smetanay, Carlo Fremd, Verena Thewes, Kathrin Haßdenteufel, Anna S Scholz, Klaus Pantel, Sabine Riethdorf, Andreas Trumpp, Andreas Schneeweiss, Laura Michel, Thomas M Deutsch","doi":"10.1159/000542830","DOIUrl":"10.1159/000542830","url":null,"abstract":"<p><strong>Introduction: </strong>Significant progress has been made in the targeted therapy of metastatic breast cancer (mBC) in recent years. In this context, new biomarkers enable personalized therapy management and individualized therapy monitoring. Therefore, the systemic treatment is based increasingly on the biological characteristics of the tumor disease. Given the challenges of obtaining fresh tumor tissue through biopsies, the significance of liquid biopsies for assessing circulating tumor cells (CTCs) or circulating tumor DNA is of growing importance for the detection of prognostic and predictive biomarkers. Multiple studies have shown that the number of CTCs decreases under therapy, especially under anti-HER2-targeted therapy, and that the expression of the HER2 status on CTCs could play a role in predicting therapy response and therapeutic monitoring. The aim of this study was to analyze the HER2 status of CTCs in mBC patients before and after 3 months of systemic therapy to evaluate changes in the number of HER2-positive CTCs. The study focuses on HER2-low, which plays an increasingly important role in clinical practice due to new developments of HER2 targeting antibody-drug conjugates. In this context, temporal and spatial heterogeneity of the disease represent a major diagnostic challenge.</p><p><strong>Methods: </strong>A total of 324 patients with complete immunohistochemistry of biopsied metastases were divided into five groups: HER2 negative (-)/hormone receptor (HR) negative (-), HER2 -/HR positive (+), HER2 +/HR±, HER2-low/HR+, and HER2-low/HR-. Before and after 3 months of a new therapeutic line for mBC, CTCs were enumerated and analyzed for HER2 expression using the CellSearch® system. Overall survival of all subgroups was calculated.</p><p><strong>Results: </strong>The analyses revealed a discrepancy between the HER2 status of CTCs and corresponding tumor tissues in 98 patients (30.2%). The number of CTCs in general and the number of HER2+ CTCs decreased during systemic treatment, mainly in HER2+ tumors, but also in the other subgroups.</p><p><strong>Conclusions: </strong>Discrepancy in the HER2 status of the metastases and of CTCs was observed in approximately one-third of patients. Measuring HER2 on CTCs could potentially offer a means to longitudinally monitor HER2 status during therapy and simultaneously address challenges such as tumor heterogeneity. Therefore, the predictive value of HER2 on CTCs should be further investigated in clinical trials.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"161-173"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142751328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating Gynecological Oncology with Different Versions of ChatGPT: A Transformative Breakthrough or the Next Black Box Challenge?","authors":"Nur Dokuzeylul Gungor, Fatih Sinan Esen, Tolga Tasci, Kagan Gungor, Kaan Cil","doi":"10.1159/000543173","DOIUrl":"10.1159/000543173","url":null,"abstract":"<p><strong>Introduction: </strong>The study evaluates the performance of large language model versions of ChatGPT - ChatGPT-3.5, ChatGPT-4, and ChatGPT-Omni - in addressing inquiries related to the diagnosis and treatment of gynecological cancers, including ovarian, endometrial, and cervical cancers.</p><p><strong>Methods: </strong>A total of 804 questions were equally distributed across four categories: true/false, multiple-choice, open-ended, and case-scenario, with each question type representing varying levels of complexity. Performance was assessed using a six-point Likert scale, focusing on accuracy, completeness, and alignment with established clinical guidelines.</p><p><strong>Results: </strong>For true/false queries, ChatGPT-Omni achieved accuracy rates of 100% for easy, 98% for medium, and 97% for complicated questions, higher than ChatGPT-4 (94%, 90%, 85%) and ChatGPT-3.5 (90%, 85%, 80%) (p = 0.041, 0.023, 0.014, respectively). In multiple-choice, ChatGPT-Omni maintained superior accuracy with 100% for easy, 98% for medium, and 93% for complicated queries, compared to ChatGPT-4 (92%, 88%, 80%) and ChatGPT-3.5 (85%, 80%, 70%) (p = 0.035, 0.028, 0.011). For open-ended questions, ChatGPT-Omni had mean Likert scores of 5.8 for easy, 5.5 for medium, and 5.2 for complex levels, outperforming ChatGPT-4 (5.4, 5.0, 4.5) and ChatGPT-3.5 (5.0, 4.5, 4.0) (p = 0.037, 0.026, 0.015). Similar trends were observed in case-scenario questions, where ChatGPT-Omni achieved scores of 5.6, 5.3, and 4.9 for easy, medium, and hard levels, respectively (p = 0.017, 0.008, 0.012).</p><p><strong>Conclusions: </strong>ChatGPT-Omni exhibited superior performance in responding to clinical queries related to gynecological cancers, underscoring its potential utility as a decision support tool and an educational resource in clinical practice.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"102-111"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Positron Emission Tomography-Computed Tomography Parameters on Pathological Response in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Treatment.","authors":"Serhat Sekmek, Ozkan Bayrakcı, Mehmet Akif Karacan, Irfan Karahan, Sema Nur Ozsan Celebi, Didem Sener Dede, Efnan Algin, Berna Okudan, Oznur Bal, Serhat Sekmek","doi":"10.1159/000545820","DOIUrl":"10.1159/000545820","url":null,"abstract":"<p><strong>Introduction: </strong>We aimed to evaluate the relationship between positron emission tomography (PET)/computed tomography (CT) parameters with pathological complete response (pCR) in patients with HER-2-positive breast cancer who received neoadjuvant treatment (NACT).</p><p><strong>Methods: </strong>This retrospective study included 97 patients. The primary endpoint was pCR. ROC analysis was used to find the cut-off values of PET/CT parameters.</p><p><strong>Results: </strong>The median age of the patients was 50.8 (24.8-77.6) years. When the factors affecting the pCR of the patients after neoadjuvant treatment were analysed, it was observed that patients with low N stage (p = 0.046), patients with high lymph node (LN) metabolic tumour volume (MTV) value (p = 0.030) and high LN total lesion glycolysis (TLG) value (p = 0.014) had more pCR in their operation pathologies after NACT. Binary logistic regression analysis showed that both low N stage (hazard ratio [HR]: 0.073, 95% confidence interval [CI]: 0.016-0.332, p = 0.001) and high LN-TLG value (HR: 0.106, 95% CI: 0.016-0.727, p = 0.022) were independent risk factors affecting pCR. LN-MTV value was not statistically significant in regression analysis (p = 0.456).</p><p><strong>Conclusion: </strong>As a result of this retrospective study, it was observed that the group with high LN-TLG, one of the PET/CT parameters, had more pCR.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"407-413"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Living Donor Liver Transplantation for Neoadjuvant-Treated, Unresectable Intrahepatic Cholangiocarcinoma (LIVINCA): Study Protocol for a One-Armed, Monocentric, Non-Randomized Trial.","authors":"Laura Schwenk, Felix Dondorf, Oliver Rohland, Aladdin Ali-Deeb, Utz Settmacher, Falk Rauchfuß, Laura Schwenk","doi":"10.1159/000545871","DOIUrl":"10.1159/000545871","url":null,"abstract":"<p><strong>Introduction: </strong>Intrahepatic cholangiocarcinoma has demonstrated a consistently increasing incidence in recent years. In cases of unresectability, palliative chemotherapy often remains the only option, typically associated with a poor prognosis. Liver transplantation might be an option for otherwise unresectable intrahepatic cholangiocarcinoma. We aimed to conduct a prospective, non-randomized study to further explore the effects of living donor liver transplantation in the treatment of unresectable neoadjuvant-treated intrahepatic cholangiocarcinoma.</p><p><strong>Methods: </strong>Patients with unresectable intrahepatic cholangiocarcinoma having a stable disease or tumor regression after systemic chemotherapy without an extrahepatic tumor burden are suitable for study inclusion. For a local control of the tumor, an additional local ablative therapy in means of a selective internal radiotherapy is mandatory. The main concept of the surgical procedure is a liver transplantation using the left (segments II-IV) or the right lobe (segments V-VIII) of a living donor. In oncosurgical optimal conditions, a two-staged hepatectomy combined with the (initially) auxiliary transplantation of a left lateral lobe of a living donor is the possible. The patient recruitment will start in September 2024.</p><p><strong>Conclusion: </strong>The design of the LIVINCA study may provide patients with otherwise unresectable intrahepatic cholangiocarcinoma a chance for a curative treatment option. This procedure does not reduce the deceased donor organ supply because living donation is the primary treatment option in these patients.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"514-523"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144064224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic Cancer Highlights from the European Society for Medical Oncology Annual Meeting 2024 in Barcelona.","authors":"Sabrina Sulzer, Marianne Sinn, Annabel Helga Sophie Alig, Anna Maxi Wandmacher","doi":"10.1159/000547154","DOIUrl":"10.1159/000547154","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"665-669"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Will Minimal Residual Disease Monitoring Be Part of Routine Surveillance?","authors":"Kerstin Pfister, Henning Schäffler, Sophia Huesmann, Sabine Heublein, Tatjana Braun, Stefan Lukac, Kristina Veselinovic, Franziska Mergel, Thomas W P Friedl, Brigitte Rack, Wolfgang Janni, Angelina Fink","doi":"10.1159/000544838","DOIUrl":"10.1159/000544838","url":null,"abstract":"<p><strong>Background: </strong>Current breast cancer (BC) surveillance is limited to the detection of local, locoregional, or contralateral recurrence. This is based on two outdated studies from the 1990s and ignores current evidence on liquid biopsies, particularly circulating tumor DNA (ctDNA).</p><p><strong>Summary: </strong>ctDNA has been shown to be a reliable prognostic biomarker in early BC surveillance. It can be detected using a tumor-informed or tumor-agnostic approach. However, conclusive evidence for a survival benefit from ctDNA-guided follow-up, as needed for a paradigm shift in BC surveillance, is still lacking. According to current studies, the lead time, i.e., the time from biomarker detection to clinically overt relapse, can be up to several months. This stage of MRD (minimal or molecular residual disease) offers a new therapeutic window, and currently, several studies are evaluating the efficacy of treatments initiated within this therapeutic window, based on a positive biomarker finding. Liquid biopsy might also open up the possibility of de-escalating therapy in patients with a negative biomarker result.</p><p><strong>Key messages: </strong>ctDNA detection predicts clinical breast cancer recurrence with high sensitivity and specificity. The interval between ctDNA detection and clinical recurrence is defined as lead time and represents a stage of molecular residual disease (MRD). ctDNA-based surveillance and adjuvant therapies have the potential to improve patient outcomes and are currently being evaluated in clinical trials.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"372-378"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143502426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence and Gynecological Oncology: A Comparative Study of ChatGPT Omni and Gemini Pro across Repeated Intervals with Case-Scenario and Open-Ended Queries.","authors":"Seckin Tuna Kaplan","doi":"10.1159/000545231","DOIUrl":"10.1159/000545231","url":null,"abstract":"<p><strong>Introduction: </strong>Artificial intelligence (AI) models offer potential benefits in supporting clinical decision-making, diagnosis, and treatment. The study aimed to compare the performance of ChatGPT-4o (Omni) and Gemini Pro in answering clinical questions and case scenarios related to gynecological oncology and to assess the consistency of their long-term responses.</p><p><strong>Methods: </strong>A two-phase comparative analysis was conducted. 700 clinical questions (350 per model) were developed and categorized into open-ended and case-scenario questions. Three months later, the same set of questions was presented again to evaluate any changes in performance for accuracy, completeness, and guideline adherence.</p><p><strong>Results: </strong>Omni outperformed Gemini Pro across all question types (p = 0.001). Omni achieved a mean score of 5.9 for the basic open-ended questions, higher than Gemini, which had 5.1 (p = 0.001). It also maintained a clear advantage in complex, open-ended questions, scoring a mean of 5.6 than Gemini AI's 4.2 (p = 0.001). Omni scored a mean of 5.7 for basic case scenarios, while Gemini AI lagged with a mean score of 5 (p = 0.001). Omni showed a modest improvement in complex, open-ended queries, with an increase of 0.2 points (+3.57%) (p = 0.001). Omni provided more accurate and comprehensive responses in guideline adherence than Gemini, particularly in complex cases requiring nuanced judgment and adherence to oncology protocols. Its responses aligned with the latest guidelines, including the American Society of Clinical Oncology and the National Comprehensive Cancer Network.</p><p><strong>Conclusion: </strong>Omni is a more reliable and consistent model for answering questions related to gynecological cancers than Gemini. The stability of Omni's performance over time highlights its potential as an effective tool for clinical applications requiring high accuracy and consistency.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"325-331"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143616708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Early Tumor Shrinkage and Depth of Response on the Clinical Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization and Lenvatinib plus PD-1 Inhibitors.","authors":"Xiaobing Zhang, Zhemin Shen, Shuping Qu, Hongyu Pan, Yalin Chen, Dong Wu","doi":"10.1159/000545210","DOIUrl":"10.1159/000545210","url":null,"abstract":"<p><strong>Introduction: </strong>Systematic therapies, including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), have now been approved as the mainstay treatment for patients with unresectable hepatocellular carcinoma (uHCC). However, only a minority of the patients are expected to respond to TKIs and ICIs. Because early tumor shrinkage (ETS) and depth of response (DoR) might have the potential to predict survival outcomes, this study aimed to identify the optimal cutoffs for ETS and DoR to predict patients' clinical outcomes in their early treatment stage.</p><p><strong>Methods: </strong>This retrospective study enrolled patients with uHCC treated with triple combination therapy of transcatheter arterial chemoembolization (TACE) and lenvatinib plus toripalimab between November 2017 and March 2022. The clinical characteristics, ETS, DoR, and overall efficacy were collected to analyze the optimal cutoffs for ETS and DoR and predict patient survival outcomes.</p><p><strong>Results: </strong>A total of 157 patients were included. The objective response rate (ORR) and disease control rate (DCR) were observed in 94 (59.87%) and 130 (82.8%) patients, respectively, with a median progression-free survival (mPFS) of 8 months and a median overall survival (mOS) of 23 months. Patients with ETS ≥10% had significantly longer mPFS (11 months) and mOS (24 months), and patients with DoR ≥27% had significantly prolonged mPFS (10 months) and mOS (23 months).</p><p><strong>Conclusion: </strong>ETS of 10% and DoR of 27% were identified as the optimal cutoffs for predicting the clinical outcomes of patients with uHCC treated with TACE and lenvatinib plus a programmed death-1 inhibitor.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"360-371"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143616709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}